RU2012153786A - Стабильные многодозовые композиции, содержащие антитело и консервант - Google Patents
Стабильные многодозовые композиции, содержащие антитело и консервант Download PDFInfo
- Publication number
- RU2012153786A RU2012153786A RU2012153786/10A RU2012153786A RU2012153786A RU 2012153786 A RU2012153786 A RU 2012153786A RU 2012153786/10 A RU2012153786/10 A RU 2012153786/10A RU 2012153786 A RU2012153786 A RU 2012153786A RU 2012153786 A RU2012153786 A RU 2012153786A
- Authority
- RU
- Russia
- Prior art keywords
- cresol
- composition according
- phenol
- chlorobutanol
- benzyl alcohol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Стабильная многодозовая жидкая композиция, содержащая антитело и один или более чем один консервант.2. Композиция по п.1, где консервант присутствует в композиции в количестве от 0,001 до 2% (вес/объем), например от 0,002 до 1% (вес/объем).3. Композиция по п.1, где один или более чем один консервант выбран среди фенола, м-крезола, бензилового спирта, хлорбутанола, этанола, феноксиэтанола, п-хлор-м-крезола, метилпарабена, пропилпарабена, бензалкония хлорида, тиомерсала или любой их комбинации, например, фенола, м-крезола, бензилового спирта и хлорбутанола.4. Композиция по п.1, которая содержит один консервант, выбранный среди фенола, м-крезола, бензилового спирта, хлорбутанола, этанола, феноксиэтанола, п-хлор-м-крезола, метилпарабена, пропилпарабена, бензалкония хлорида и тиомерсала, например фенол, м-крезол, бензиловый спирт и хлорбутанола.5. Композиция по п.1, которая содержит два или более двух консервантов, выбранных среди фенола, м-крезола, бензилового спирта, хлорбутанола, этанола, феноксиэтанола, п-хлор-м-крезола, метилпарабена, пропилпарабена, бензалкония хлорида, тиомерсала или любой их комбинации, в частности фенола и м-крезола; бензилового спирта и хлорбутанола.6. Композиция по п.1, которая буферизована до рН от 5 до 7, например до рН от 6,0 до 7,0, например 6,0 или 6,5, в частности 6,5.7. Композиция по п.1, которая дополнительно содержит агент, модифицирующий тоничность, такой как сахарозу или пропиленгликоль.8. Композиция по п.1, где антитело присутствует в композиции в концентрации 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250 или 300 мг/мл.9. Композиция по п.1, в которой поверхностно-активное вещество отсутствует.10. Композиция по п.1, которая включает:(A
Claims (15)
1. Стабильная многодозовая жидкая композиция, содержащая антитело и один или более чем один консервант.
2. Композиция по п.1, где консервант присутствует в композиции в количестве от 0,001 до 2% (вес/объем), например от 0,002 до 1% (вес/объем).
3. Композиция по п.1, где один или более чем один консервант выбран среди фенола, м-крезола, бензилового спирта, хлорбутанола, этанола, феноксиэтанола, п-хлор-м-крезола, метилпарабена, пропилпарабена, бензалкония хлорида, тиомерсала или любой их комбинации, например, фенола, м-крезола, бензилового спирта и хлорбутанола.
4. Композиция по п.1, которая содержит один консервант, выбранный среди фенола, м-крезола, бензилового спирта, хлорбутанола, этанола, феноксиэтанола, п-хлор-м-крезола, метилпарабена, пропилпарабена, бензалкония хлорида и тиомерсала, например фенол, м-крезол, бензиловый спирт и хлорбутанола.
5. Композиция по п.1, которая содержит два или более двух консервантов, выбранных среди фенола, м-крезола, бензилового спирта, хлорбутанола, этанола, феноксиэтанола, п-хлор-м-крезола, метилпарабена, пропилпарабена, бензалкония хлорида, тиомерсала или любой их комбинации, в частности фенола и м-крезола; бензилового спирта и хлорбутанола.
6. Композиция по п.1, которая буферизована до рН от 5 до 7, например до рН от 6,0 до 7,0, например 6,0 или 6,5, в частности 6,5.
7. Композиция по п.1, которая дополнительно содержит агент, модифицирующий тоничность, такой как сахарозу или пропиленгликоль.
8. Композиция по п.1, где антитело присутствует в композиции в концентрации 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250 или 300 мг/мл.
9. Композиция по п.1, в которой поверхностно-активное вещество отсутствует.
10. Композиция по п.1, которая включает:
(A) 100 мг/мл антитела;
(B) 25 мМ хлорида натрия;
(C) 33 мМ гистидинового буфера;
(D) 25 мМ аргинина;
(Е) 0,001% полисорбата 80;
(F) 1,5 мг/мл фенола и 1,8 мг/мл м-крезола;
(G) 120 мМ сахарозы;
и буферизована до рН 6,5.
11. Композиция по п.1, которая включает:
(A) 100 мг/мл антитела;
(B) 25 мМ хлорида натрия;
(C) 33 мМ гистидинового буфера;
(D) 25 мМ аргинина;
(Е) 0,01% полисорбата 80;
(F) 1,5 мг/мл фенола и 1,8 мг/мл м-крезола;
(G) 120 мМ сахарозы;
и буферизована до рН 6,5.
12. Композиция по п.1, которая включает:
(A) 100 мг/мл антитела;
(B) 25 мМ хлорида натрия;
(C) 33 мМ гистидинового буфера;
(D) 25 мМ аргинина;
(Е) 0,01% полисорбата 80;
(F) 1,5 мг/мл фенола и 1,8 мг/мл м-крезола;
(G) 120 мМ сахарозы;
и буферизована до рН 6.
13. Стабильная композиция антитела по любому из пп.1-10 для применения в терапии.
14. Стабильная композиция антитела по любому из пп.1-11 для применения в лечении воспалительного заболевания.
15. Стабильная композиция по любому из пп.1-11 для применения в лечении коагулопатии.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10164298.1 | 2010-05-28 | ||
EP10164298 | 2010-05-28 | ||
US35152210P | 2010-06-04 | 2010-06-04 | |
US61/351,522 | 2010-06-04 | ||
PCT/EP2011/058648 WO2011147921A1 (en) | 2010-05-28 | 2011-05-26 | Stable multi-dose compositions comprising an antibody and a preservative |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012153786A true RU2012153786A (ru) | 2014-07-10 |
Family
ID=42562357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012153786/10A RU2012153786A (ru) | 2010-05-28 | 2011-05-26 | Стабильные многодозовые композиции, содержащие антитело и консервант |
Country Status (11)
Country | Link |
---|---|
US (2) | US20130136733A1 (ru) |
EP (1) | EP2575761A1 (ru) |
JP (3) | JP6294075B2 (ru) |
KR (1) | KR20130086144A (ru) |
CN (2) | CN105055306B (ru) |
AU (1) | AU2011257219B2 (ru) |
BR (1) | BR112012030139A2 (ru) |
CA (1) | CA2800188A1 (ru) |
MX (1) | MX2012013586A (ru) |
RU (1) | RU2012153786A (ru) |
WO (1) | WO2011147921A1 (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2561828T3 (es) | 2002-01-25 | 2016-03-01 | Novo Nordisk A/S | Anticuerpos monoclonales contra bucles extracelulares de C5aR |
JP2011515073A (ja) | 2008-02-20 | 2011-05-19 | ジーツー インフラメイション プロプライエタリー リミテッド | ヒト化抗C5aR抗体 |
EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
EP3216462A3 (en) * | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
ES2642512T3 (es) | 2010-03-01 | 2017-11-16 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI) |
CN105055306B (zh) | 2010-05-28 | 2019-10-01 | 诺沃—诺迪斯克有限公司 | 包含抗体和防腐剂的稳定的多剂量组合物 |
DK3424953T3 (en) | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
US10316095B2 (en) * | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
ES2702246T3 (es) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Formulaciones de agente de unión IgG4 estables |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
BR112018001478A2 (pt) | 2015-08-19 | 2018-09-18 | Pfizer Inc. | anticorpos do inibidor da via do fator de tecidos e uso dos mesmos |
EP3618864A1 (en) * | 2017-05-05 | 2020-03-11 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
BR112021004590A2 (pt) | 2018-09-12 | 2021-05-25 | Silverback Therapeutics, Inc. | composições para o tratamento de doença com conjugados imunoestimuladores |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
MX2021015533A (es) | 2019-06-19 | 2022-02-10 | Silverback Therapeutics Inc | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. |
BR112022007635A2 (pt) * | 2019-11-13 | 2022-07-12 | Pfizer | Formulação aquosa e estável de anticorpos |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
CA3194881A1 (en) | 2020-08-12 | 2022-02-17 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
US20230357432A1 (en) * | 2020-09-24 | 2023-11-09 | Novo Nordisk Health A/S | Pharmaceutical formulation of concizumab and method of production thereof |
CN112244025A (zh) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用 |
WO2024090488A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物 |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JP3681206B2 (ja) | 1995-12-26 | 2005-08-10 | 株式会社三菱化学ヤトロン | 抗ファクターXa・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用 |
KR100374737B1 (ko) | 1996-06-28 | 2003-07-16 | 세이코 엡슨 가부시키가이샤 | 트랜지스터형성방법,그트랜지스터를포함하는회로,액티브매트릭스기판의제조방법,표시장치의제조방법,및프로젝터및전자기기 |
US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
CA2264548A1 (en) | 1996-08-30 | 1998-03-05 | Human Genome Sciences, Inc. | Interleukin-19 |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
CA2296762A1 (en) | 1997-07-16 | 1999-01-28 | Human Genome Sciences, Inc. | Interleukin-20 |
US6486301B1 (en) | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
JP2001512668A (ja) | 1997-08-06 | 2001-08-28 | ザイモジェネティクス,インコーポレイティド | リポカリン相同体 |
US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
DE69918946T2 (de) | 1998-01-23 | 2005-07-28 | Immunex Corp., Seattle | Rezeptoren für il-18 |
AU2871899A (en) | 1998-03-09 | 1999-09-27 | Schering Corporation | Human receptor proteins; related reagents and methods |
NZ507435A (en) | 1998-03-10 | 2003-12-19 | Genentech Inc | Novel polypeptides and nucleic acids with homology to cornichon |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
AU4411699A (en) | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Interferon receptor hkaef92 |
US6936697B2 (en) | 1998-09-01 | 2005-08-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
BR9913857A (pt) | 1998-09-17 | 2001-06-12 | Lilly Co Eli | Formulações de proteìna |
US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
EP1141008A1 (en) | 1998-12-31 | 2001-10-10 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
US20050060101A1 (en) | 1999-06-28 | 2005-03-17 | Bevilacqua Michael P. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
CA2386228A1 (en) | 1999-10-04 | 2001-04-12 | Chiron Corporation | Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides |
KR100399156B1 (ko) * | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
AU783473B2 (en) | 1999-12-23 | 2005-10-27 | Zymogenetics Inc. | Soluble interleukin-20 receptor |
IL152130A0 (en) | 2000-04-07 | 2003-05-29 | Ellis L Kline | Methods and compositions for treating neoplasms |
US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
EP2177616B1 (en) | 2000-08-08 | 2012-02-29 | ZymoGenetics, Inc. | Soluble zcytor 11 cytokine receptors |
ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
CA2433933A1 (en) | 2001-02-28 | 2002-09-12 | Eli Lilly And Company | Use of lp82 to treat hematopoietic disorders |
DK1399472T3 (da) | 2001-03-09 | 2009-10-05 | Zymogenetics Inc | Oplöselig heterodimer cytokinreceptor |
CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
CA2460916A1 (en) | 2001-10-04 | 2003-04-10 | Laura Carter | Methods and compositions for modulating interleukin-21 receptor activity |
US7022289B1 (en) | 2001-10-10 | 2006-04-04 | The United States Of America As Represented By The Secretary Of The Army | Chemical and biological sampling device and kit and method of use thereof |
CN100374457C (zh) * | 2001-11-14 | 2008-03-12 | 森托科尔公司 | 抗il-6抗体、组合物、方法和用途 |
AU2002357283B2 (en) | 2001-12-17 | 2007-08-16 | Zymogenetics, Inc. | Method for treating cervical cancer |
KR101080021B1 (ko) | 2002-02-14 | 2011-11-04 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
AU2003219958B2 (en) | 2002-02-27 | 2006-01-05 | Immunex Corporation | Polypeptide formulation |
AU2003226141A1 (en) | 2002-03-27 | 2003-10-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for treating cancer in humans |
US20040009168A1 (en) * | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
AU2005254062B2 (en) | 2002-04-11 | 2011-02-17 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
EP2377547A1 (en) | 2002-06-07 | 2011-10-19 | ZymoGenetics, Inc. | Use of IL-21 as an antimicrobial agent |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
AU2003251592A1 (en) | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
BR0312767A (pt) | 2002-07-18 | 2005-05-03 | Perini Fabio Spa | Unidade de armazenamento para produtos alongados |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
KR20050110628A (ko) | 2003-02-10 | 2005-11-23 | 엘란 파마슈티칼스, 인크. | 면역글로불린 제제 및 이의 제조방법 |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
MXPA06000583A (es) | 2003-07-15 | 2006-03-30 | Amgen Inc | Anticuerpos neutralizantes anti-ngf humano como inhibidores selectivos de la via del ngf. |
CN100522998C (zh) | 2003-10-01 | 2009-08-05 | 协和发酵麒麟株式会社 | 抗体的稳定化方法和被稳定的溶液状抗体制剂 |
JPWO2005063291A1 (ja) | 2003-12-25 | 2007-07-19 | 麒麟麦酒株式会社 | 抗体を含有する安定な水性医薬製剤 |
DK1812476T3 (da) | 2004-10-22 | 2010-10-25 | Zymogenetics Inc | Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation |
CA2596390A1 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
US7525604B2 (en) | 2005-03-15 | 2009-04-28 | Naxellent, Llc | Windows with electrically controllable transmission and reflection |
ATE501248T1 (de) | 2005-07-02 | 2011-03-15 | Arecor Ltd | Stabile wässrige systeme mit proteinen |
WO2007006858A2 (en) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
AU2006295340B2 (en) * | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
WO2007038754A2 (en) | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
US20080071063A1 (en) | 2006-02-03 | 2008-03-20 | Medimmune, Inc. | Protein Formulations |
DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
JP2009530699A (ja) | 2006-03-15 | 2009-08-27 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | ロール検出を備えたリモートコントロール型ポインティング技術 |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
WO2007108559A1 (ja) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
EP1998806A1 (en) * | 2006-03-28 | 2008-12-10 | F. Hoffmann-Roche AG | Anti-igf-1r human monoclonal antibody formulation |
EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
MX2008015852A (es) | 2006-06-14 | 2009-02-23 | Imclone Systems Inc | Formulaciones liofilizadas de anticuerpos anti-egfr. |
BRPI0713133A2 (pt) | 2006-06-19 | 2012-03-27 | Wyeth Corp | métodos de modular il-22 e il-17 |
EP2038306B1 (en) | 2006-06-30 | 2014-12-03 | Novo Nordisk A/S | Anti-nkg2a antibodies and uses thereof |
AU2007307107B2 (en) | 2006-10-06 | 2011-11-03 | Amgen Inc. | Stable antibody formulations |
EP2076287A2 (en) | 2006-10-12 | 2009-07-08 | Wyeth | Methods and compositions with reduced opalescence |
WO2008048986A2 (en) | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
JP2010508838A (ja) | 2006-11-09 | 2010-03-25 | アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル(イーエヌエスエーエールエム) | TNF−α遮断薬に対する治療応答性の予測方法 |
CA2671968A1 (en) | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
CL2008000058A1 (es) | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
EP2132343B1 (en) | 2007-03-01 | 2012-08-29 | Université Catholique de Louvain | Method for the determination and the classification of rheumatic conditions |
JP5152177B2 (ja) | 2007-03-23 | 2013-02-27 | パナソニック株式会社 | 導電性バンプとその製造方法および電子部品実装構造体 |
EP2703007A1 (en) | 2007-03-30 | 2014-03-05 | MedImmune, LLC | Antibodies with decreased deamidation profiles |
GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
KR20100037590A (ko) | 2007-06-08 | 2010-04-09 | 바이오겐 아이덱 엠에이 인코포레이티드 | 항 tnf 반응 또는 무반응을 예측하기 위한 바이오마커 |
US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
LT2170390T (lt) | 2007-06-14 | 2019-01-10 | Biogen Ma Inc. | Natalizumabo antikūnų kompozicijos |
WO2008157282A1 (en) | 2007-06-18 | 2008-12-24 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
CA2692165A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
JP2010532790A (ja) | 2007-07-06 | 2010-10-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗体処方 |
UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
US20110143351A1 (en) | 2007-07-20 | 2011-06-16 | National Institute For Biopr0Essing Research And Training Limited | Glyosylation markers for cancer and chronic inflammation |
WO2009015398A1 (en) | 2007-07-26 | 2009-01-29 | Oklahoma Medical Research Foundation | Methods for inflammatory disease management |
EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
AU2008337517B2 (en) | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
JP2011515073A (ja) | 2008-02-20 | 2011-05-19 | ジーツー インフラメイション プロプライエタリー リミテッド | ヒト化抗C5aR抗体 |
WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
JP2011523408A (ja) | 2008-05-15 | 2011-08-11 | ノボ・ノルデイスク・エー/エス | 抗体精製方法 |
TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
RU2011105466A (ru) | 2008-08-28 | 2012-10-10 | ВАЙЕТ ЭлЭлСи (US) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях |
PE20110302A1 (es) | 2008-09-19 | 2011-05-21 | Hoffmann La Roche | Formulacion farmaceutica de un anticuerpo contra p-selectina |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
EP2379600B2 (en) | 2008-12-22 | 2020-10-14 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
US20120020954A1 (en) | 2009-03-30 | 2012-01-26 | Anat Achiron | Methods of predicting clinical course and treating multiple sclerosis |
MX2012002766A (es) | 2009-09-03 | 2012-04-02 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
US8580528B2 (en) | 2009-10-16 | 2013-11-12 | Stichting Vu-Vumc | Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy |
WO2011047073A2 (en) | 2009-10-16 | 2011-04-21 | Mayo Foundation For Medical Education And Research | Assessing rheumatoid arthritis |
EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
CN105055306B (zh) | 2010-05-28 | 2019-10-01 | 诺沃—诺迪斯克有限公司 | 包含抗体和防腐剂的稳定的多剂量组合物 |
WO2011154139A2 (en) | 2010-06-07 | 2011-12-15 | Roche Diagnostics Gmbh | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
-
2011
- 2011-05-26 CN CN201510485529.1A patent/CN105055306B/zh active Active
- 2011-05-26 EP EP11721544.2A patent/EP2575761A1/en active Pending
- 2011-05-26 WO PCT/EP2011/058648 patent/WO2011147921A1/en active Application Filing
- 2011-05-26 US US13/699,847 patent/US20130136733A1/en not_active Abandoned
- 2011-05-26 RU RU2012153786/10A patent/RU2012153786A/ru unknown
- 2011-05-26 MX MX2012013586A patent/MX2012013586A/es unknown
- 2011-05-26 KR KR1020127030515A patent/KR20130086144A/ko not_active Application Discontinuation
- 2011-05-26 CN CN201180026538.4A patent/CN102905692B/zh active Active
- 2011-05-26 CA CA2800188A patent/CA2800188A1/en not_active Withdrawn
- 2011-05-26 AU AU2011257219A patent/AU2011257219B2/en not_active Withdrawn - After Issue
- 2011-05-26 BR BR112012030139A patent/BR112012030139A2/pt not_active IP Right Cessation
- 2011-05-26 JP JP2013511686A patent/JP6294075B2/ja active Active
-
2016
- 2016-02-09 JP JP2016022657A patent/JP6239657B2/ja active Active
-
2017
- 2017-10-31 US US15/799,276 patent/US10835602B2/en active Active
- 2017-11-01 JP JP2017211614A patent/JP6568917B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6239657B2 (ja) | 2017-11-29 |
JP6294075B2 (ja) | 2018-03-14 |
BR112012030139A2 (pt) | 2017-06-13 |
MX2012013586A (es) | 2013-01-24 |
CN102905692A (zh) | 2013-01-30 |
CA2800188A1 (en) | 2011-12-01 |
US20180104335A1 (en) | 2018-04-19 |
CN105055306B (zh) | 2019-10-01 |
US20130136733A1 (en) | 2013-05-30 |
AU2011257219A1 (en) | 2012-11-22 |
JP2013527189A (ja) | 2013-06-27 |
JP2016084367A (ja) | 2016-05-19 |
CN105055306A (zh) | 2015-11-18 |
EP2575761A1 (en) | 2013-04-10 |
JP2018030879A (ja) | 2018-03-01 |
WO2011147921A1 (en) | 2011-12-01 |
CN102905692B (zh) | 2015-09-16 |
JP6568917B2 (ja) | 2019-08-28 |
AU2011257219B2 (en) | 2014-12-04 |
US10835602B2 (en) | 2020-11-17 |
KR20130086144A (ko) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012153786A (ru) | Стабильные многодозовые композиции, содержащие антитело и консервант | |
JP2013527189A5 (ru) | ||
RU2015132431A (ru) | Составы, содержащие антитела | |
ES2324058T3 (es) | Solucion oftalmica de bimatoprost mejorada. | |
EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
EA201492021A1 (ru) | Антительный состав | |
RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
PE20170948A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
EA201201309A1 (ru) | Фармацевтически активные производные двузамещенного триазина | |
MY193913A (en) | Stable Protein Solution Formulation Containing High Concentration of an Anti-Vegf Antibody | |
AR095396A1 (es) | Formulaciones de anticuerpo | |
MA31953B1 (fr) | Nouveaux derives du thiophene. | |
BR112015008186A2 (pt) | formulação de um anticorpo estável e de baixa viscosidade | |
JP2015531374A5 (ru) | ||
EA201200939A1 (ru) | Липиды, липидные композиции и способы их применения | |
EA201590758A1 (ru) | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина | |
AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
EA201500432A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
AR060487A1 (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 | |
EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
EA201071288A1 (ru) | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина | |
RU2010139958A (ru) | Стабилизированная фармацевтическая композиция, cодержащая доцетаксель | |
AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
EA200970274A1 (ru) | Способы введения гипогликемических средств с длительным действием | |
EA201300539A1 (ru) | Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA91 | Application withdrawn (on applicant's request) |
Effective date: 20150211 |